EUROPEAN OPHTHALMIC REVIEW – VOLUME 8 ISSUE 2 – WINTER 2014

The current issue of European Ophthalmic Review presents a stimulating mix of expert reviews, case studies and reportage from the ophthalmology society meetings. Satellite symposia reports feature the subjects of aflibercept in diabetic macular oedema (DMO) (Korobelnik et al.) and DMO management, in particular relating to corticosteroid use (Augustin et al.) Quhill and Paulo and […]

Proceedings of a Symposium Presented at the International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) 2014 in Reykjavik, Iceland, 20 June 2014 Pathogenetic Considerations and Implications on Simplified Decision-making in Dry Eye Disease Marc Labetoulle Ophthalmology Department, Bicêtre Hospital, Assistance Publique – Hôpitaux de Paris, South Paris University, France Dry eye disease (DED) is a […]

Since the introduction of ultrasound phacoemulsification in 1967, cataract surgery has become the most commonly performed outpatient operation in the US. While phacoemulsification has shown to be safe and effective, application of ultrasound power within the eye does carry some risk for ocular injury, such as endothelial cell loss. In addition, the manual method of […]

The best flap thickness has traditionally been considered to be 130 μm to 160 μm in order to preserve a greater amount of residual stromal bed (RSB). The demand to correct larger amounts of ametropia, the development of customised ablation techniques with a trend towards enlarging the diameter of laser ablations, the inducement of aberrations […]

Glaucoma affects over 60 million people worldwide and after cataract is the second leading cause of irreversible blindness; its prevalence is increasing due to the ageing of the population.1 If we consider the direct and indirect costs of glaucoma there is an increase in the global cost and the economic burden as glaucoma worsens.2,3 Also […]

Proceedings of a Symposium Presented at the European Glaucoma Society (EGS) Congress in Nice, 9 June 2014 How to Bring Risk Factors into Clinical Management of Glaucoma Lutz Pillunat University Eye Hospital Dresden, Germany Multiple risk factors are associated with poor outcomes in glaucoma, including intraocular pressure (IOP), vascular factors, neurodegeneration, central corneal thickness, optic […]

Glaucoma is a disease that results in degeneration of the optic disc and can lead to reduced vision and even blindness if left untreated. The purpose of this article is to provide summary results of Trabectome procedures performed between 2004 to 2014. Glaucoma remains one of the leading causes of blindness worldwide. Globally, 60.5 million […]

Visual impairment has a large effect on societal health costs. It has been estimated that the annual cost of major adult visual disorders, including visual impairment, blindness, age-related macular degeneration (AMD), cataracts, diabetic retinopathy (DR), glaucoma and refractive errors, account for a total annual financial burden of $35.4 billion1,2 in the US alone. These costs […]

Fabry disease (FD) is a rare, X-linked, lysosomal storage disorder with a reported incidence of 1:117,000 live births.1 However, due to the pan-ethnic nature of FD, reported incidence rates of 1:117,000 may underestimate the true prevalence of the disease, which have been recorded as high as 1:3,100 live births.2,3 FD is caused by mutations in […]

Optical coherence tomography (OCT) has revolutionised eye care and significantly improved our understanding of a number of retinal diseases.1 This non-invasive imaging technique utilises lowcoherence interferometry to create cross-sectional images, measuring backscattered or back-reflected light. The first commercially available devices used time domain modality (TD-OCT) and were designed to visualise the retina at 10 μm […]

Diabetic retinopathy (DR) is the most common cause of moderate-tosevere visual impairment among working class adults.1 Diabetic macular oedema (DMO), a common manifestation of DR, causes central vision loss,2 and is a consequence of vascular inner blood–retinal barrier breakdown.3 Global prevalence of DR among diabetic individuals is approximately 35 %, with DMO present in 6.8 […]

The International Diabetes Federation (IDF) estimated that 8.3 % of adults (or 382 million) had diabetes in 2013.1 This is significantly higher than previous estimates (2.8 % or 171 million adults).2 Diabetic retinopathy (DR) is a potentially sight-threatening disease affecting the retinal microvasculature and associated with prolonged hyperglycaemia and other conditions linked to diabetes mellitus […]

Proceedings of a Symposium Presented at the 14th EURETINA Congress, London, 12th September 2014 Diabetic macular oedema (DMO) is a serious threat to vision that is showing increasing prevalence as a consequence of the worldwide increase in both type I and type II diabetes.1 DMO affects approximately 7 % of people with diabetes and is […]

Diabetic macular oedema (DMO) is an increasingly common visionthreatening disease that results from retinal vascular dysfunction and low-grade inflammation, developing into diabetic retinopathy (DR) and then to DMO over 10 or more years following the onset of diabetes.1 Areas of retinal tissue lose capillary vasculature and become ischaemic, stimulating secretion of vascular endothelial growth factor […]